Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H18N4O2.ClH |
| Molecular Weight | 370.833 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=C(C=C1)C2=NC3=C(N2)C=CC(=C3)C4=NNC(=O)CC4C
InChI
InChIKey=OJLOGBZTFKPHDQ-UHFFFAOYSA-N
InChI=1S/C19H18N4O2.ClH/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12;/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H18N4O2 |
| Molecular Weight | 334.3718 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1660359
Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi, and Heartmedin) is a veterinary medication. Under the trade name Acardi, it is available for human use in Japan. Usually, this medicine is used to treat acute heart failure and chronic heart failure (mild to moderate in severity). By increasing the calcium ion sensitivity to protein regulating myocardial contraction and also by inhibiting phosphodiesterase (PDE-III) activity, this medicine dilates the blood vessels and improves the symptoms of heart failure such as shortness of breath and difficulty in breathing. Pimobendan is metabolized into an active metabolite (desmethylpimobendan) by the liver. The parent compound, pimobendan, is a potent calcium sensitizer while desmethylpimobendan is a more potent phosphodiesterase III inhibitor. Pimobendan is 90–95% bound to plasma proteins in circulation. This may have implications in patients suffering from low blood protein levels (hypoproteinemia/hypoalbuminemia) and in patients that are on concurrent therapies that are also highly protein bound.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Differential modulation of cytokine production by drugs: implications for therapy in heart failure. | 1996 Dec |
|
| The novel insulinotropic mechanism of pimobendan: direct enhancement of the exocytotic process of insulin secretory granules by increased Ca2+ sensitivity in beta-cells. | 1998 Mar |
|
| A case of severe hypoglycemia due to pimobendan. | 2001 Aug |
|
| Increase in myofibrillar Ca2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium. | 2001 Feb |
|
| Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction. | 2001 Oct |
|
| Mechanism of action of Ca2+ sensitizers--update 2001. | 2001 Sep |
|
| Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium. | 2001 Sep |
|
| Effect of pimobendan in patients with chronic heart failure. | 2001 Winter |
|
| Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. | 2002 Dec |
|
| Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status. | 2002 Dec |
|
| Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). | 2002 Feb |
|
| Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases. | 2002 May |
|
| Combined endpoints: can we use them? | 2002 Oct 15 |
|
| [Pharmacological treatment of heart failure]. | 2003 Apr |
|
| Role of nonglycosidic inotropic agents: indications, ethics, and limitations. | 2003 Mar |
|
| Inhibition and facilitation by pimobendan, a calcium sensitizer, of catecholamine secretion from bovine adrenal chromaffin cells. | 2003 Mar |
|
| Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. | 2003 Mar |
|
| [Inotropic agents]. | 2003 May |
|
| [Roles of cytokines in the pathogenesis of heart failure]. | 2003 May |
|
| The role of Ca++-sensitizers for the treatment of heart failure. | 2003 Oct |
|
| Do medical house officers value the health of veterans differently from the health of non-veterans? | 2004 Apr 7 |
|
| Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy. | 2004 Sep |
|
| Use of pimobendan in the management of heart failure. | 2004 Sep |
|
| [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency]. | 2005 Apr 15 |
|
| [Cytokine antagonists and endothelin antagonists for therapy of heart failure]. | 2005 Feb 10 |
|
| Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. | 2005 Mar |
|
| A review of levosimendan in the treatment of heart failure. | 2006 |
|
| Pimobendan in heart failure therapy--a silver bullet? | 2006 Mar-Apr |
|
| [Subarachnoid hemorrhage complicated with different manifestations of transient abnormal left ventricular wall motion: two case reports]. | 2006 May |
|
| Preclinical dilated cardiomyopathy in the dobermann. | 2006 May 27 |
|
| Acute heart failure: inotropic agents and their clinical uses. | 2006 Nov |
|
| New insights in the treatment strategy for pulmonary arterial hypertension. | 2006 Oct |
|
| Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. | 2007 Jul-Aug |
|
| Treatment options in myocarditis: what we know from experimental data and how it translates to clinical trials. | 2007 Sep |
|
| Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs. | 2008 Apr |
|
| Cardiac Ca2+ signaling and Ca2+ sensitizers. | 2008 Dec |
|
| The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy. | 2008 Jul 9 |
|
| Anaesthesia for the geriatric dog and cat. | 2008 Jun 1 |
|
| Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study". | 2008 Mar-Apr |
|
| Alterations in vasomotor control of coronary resistance vessels in remodelled myocardium of swine with a recent myocardial infarction. | 2008 May |
|
| Chronic cor pulmonale secondary to pulmonary atherosclerosis in an African Grey parrot. | 2009 Apr 15 |
|
| Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. | 2009 Nov-Dec |
|
| Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism. | 2009 Sep-Oct |
|
| Sarcomere control mechanisms and the dynamics of the cardiac cycle. | 2010 |
|
| Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases. | 2010 Aug |
|
| Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies. | 2010 Jan 18 |
|
| Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. | 2010 Jul |
|
| Current use of pimobendan in canine patients with heart disease. | 2010 Jul |
|
| Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives. | 2010 Jun 1 |
|
| Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
Sample Use Guides
Acute heart failure: usually for adults, one capsule (2.5 mg of pimobendan) once daily
Chronic heart failure (mild to moderate in severity): usually for adults, one capsule (2.5 mg of pimobendan) twice daily after meals
Route of Administration:
Oral
composite platelet aggregation (area under the curve [AUC]) and maximal platelet aggregation (aggregation units [AUs]) at 10.0μM pimobendan were significantly decreased for collagen-induced aggregation (AUC, 349.7 ± 58.4 vs 285.1 ± 72.2; maximal platelet aggregation, 196.2 ± 25.8 AUs vs 161.5 ± 38.0 AUs), and the AUC and velocity of aggregation at 10.0μM pimobendan were significantly decreased for ADP-induced aggregation (AUC, 268.5 ± 35.1 vs 213.4 ± 77.2; velocity of aggregation, 15.7 ± 2.9 AUs/min vs 11.8 ± 3.5 AUs/min).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:23:53 GMT 2023
by
admin
on
Sat Dec 16 09:23:53 GMT 2023
|
| Record UNII |
7595Q8C89H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
77469-98-8
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | |||
|
7595Q8C89H
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | |||
|
74149-75-0
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
10126299
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | |||
|
m8815
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID0046804
Created by
admin on Sat Dec 16 09:23:53 GMT 2023 , Edited by admin on Sat Dec 16 09:23:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE |
